Compare ELME & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | VYGR |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.9M | 203.6M |
| IPO Year | 1994 | 2015 |
| Metric | ELME | VYGR |
|---|---|---|
| Price | $1.51 | $3.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $12.67 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 2.2M | 752.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 707.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | $10,135,000.00 |
| Revenue This Year | $5.03 | $34.04 |
| Revenue Next Year | $4.31 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $2.88 |
| 52 Week High | $17.68 | $5.55 |
| Indicator | ELME | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 38.47 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.62 | $4.33 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 25.52 | 17.46 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.